Art

J-GLOBAL ID：202302226931135643   Reference number：23A2211097

Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond

HER2変異非小細胞肺癌の進化治療景観:トラスツズマブDerxtecanおよびその他【JST・京大機械翻訳】

Author (4)： Vathiotis Ioannis A. (Third Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece) ,  Bafaloukos Dimitrios (First Oncology Department, Metropolitan Hospital, 18547 Athens, Greece) ,  Syrigos Konstantinos N. (Third Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece) ,  Samonis George (First Oncology Department, Metropolitan Hospital, 18547 Athens, Greece)
Material： Cancers (Web)
Volume： 15  Issue： 4  Page： 1286  Publication year： 2023 
JST Material Number： U7153A  ISSN： 2072-6694  Document type： Article
Article type： 文献レビュー  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： Successful targeting of HER2-a...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=23A2211097&from=J-GLOBAL&jstjournalNo=U7153A") }}

Thesaurus term： *biological preparation ,  central nervous system ,  *variation(biology) ,  gene expression ,  *monoclonal antibody ,  targeting ,  *non-small cell lung cancer ,  *molecular targeting drug
Semi thesaurus term： *トラスツズマブ ,  過剰発現 ,  抗体薬物複合体 , 【Automatic Indexing@JST】

Author keywords (3)： NSCLC ,  HER2 ,  trastuzumab

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Reference (69)：

• Goto, K.; Sang-We, K.; Kubo, T.; Goto, Y.; Ahn, M.-J.; Planchard, D.; Kim, D.-W.; Yang, J.-H.; Yang, T.-Y.; Pereira, K.; et al. LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial. Ann. Oncol. 2022, 33, S1422.
• Ogitani, Y.; Aida, T.; Hagihara, K.; Yamaguchi, J.; Ishii, C.; Harada, N.; Soma, M.; Okamoto, H.; Oitate, M.; Arakawa, S.; et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin. Cancer Res. 2016, 22, 5097-5108.
• National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 1.2023). Available online: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (accessed on 18 January 2023).
• Ren, S.; Wang, J.; Ying, J.; Mitsudomi, T.; Lee, D.; Wang, Z.; Chu, Q.; Mack, P.; Cheng, Y.; Duan, J.; et al. Consensus for HER2 alterations testing in non-small-cell lung cancer. ESMO Open 2022, 7, 100395.
• Robichaux, J.P.; Elamin, Y.Y.; Vijayan, R.; Nilsson, M.B.; Hu, L.; He, J.; Zhang, F.; Pisegna, M.; Poteete, A.; Sun, H.; et al. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 2019, 36, 444-457.e7.

Terms in the title (7)： HER2 ,  変異 ,  非小細胞肺癌 ,  進化 ,  治療 ,  景観 ,  トラスツズマブ